Get the Stockscreener App
10.48
0.05%
-0.11
Elicio Therapeutics Inc stock is traded at $10.48, with a volume of 24,047.
It is down -0.05% in the last 24 hours and down -0.80% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
See More
Previous Close:
$10.59
Open:
$10.69
24h Volume:
24,047
Relative Volume:
0.17
Market Cap:
$196.21M
Revenue:
-
Net Income/Loss:
$-39.57M
P/E Ratio:
-4.0926
EPS:
-2.5607
Net Cash Flow:
$-36.97M
1W Performance:
+2.57%
1M Performance:
-0.80%
6M Performance:
+16.70%
1Y Performance:
+106.34%
1-Day Range:
$10.29
$10.69
1-Week Range:
$10.12
$11.21
52-Week Range:
$4.85
$14.93
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
10.49 | 198.08M | 0 | -39.57M | -36.97M | -2.5607 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Ladenburg Thalmann | Buy |
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Elicio Therapeutics lines up May 14 investor webcast in Las Vegas - Stock Titan
elicio-ex311to10xk_aapri.htm - SEC.gov
elicio-ex312to10xk_aapri.htm - SEC.gov
Elicio Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
[10-K/A] Elicio Therapeutics, Inc. Amends Annual Report - Stock Titan
Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out - Seeking Alpha
Wall Street analysts predict a 42.28% upside in Elicio Therapeutics (ELTX): Here's what you should know - MSN
Understanding Momentum Shifts in (ELTX) - Stock Traders Daily
Is Elicio Therapeutics (ELTX) stock outperforming similar companies | Q4 2025: EPS Beats ForecastsCycle Outlook - Cổng thông tin điện tử tỉnh Lào Cai
ELTX (Elicio Therapeutics Inc.) narrowly tops Q4 2025 earnings estimates, shares post modest 0.43 percent gain today.Rating Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Elicio Therapeutics (ELTX) Stock Most Held Stocks (Technical Weakness) 2026-04-20Social Flow Trades - Xã Thanh Hà
Elicio Therapeutics (ELTX) Stock: Mid-Year Review (Trend Strengthens) 2026-04-18Community Buy Alerts - Cổng thông tin điện tử Tỉnh Sơn La
New Elicio hire gets 21,210 stock options at $11.78 a share - Stock Titan
Avoiding Lag: Real-Time Signals in (ELTX) Movement - Stock Traders Daily
ELTX SEC FilingsElicio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Ladenburg Thalmann initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
Is Elicio Therapeutics (ELTX) Stock Attractive Now | ELTX Q4 Earnings: Beats Estimates by $0.00Trading Community - Cổng thông tin điện tử tỉnh Tây Ninh
Dip Buying: How do insiders feel about Elicio Therapeutics IncTrade Risk Assessment & Weekly Setup with High ROI Potential - baoquankhu1.vn
Aug Big Picture: Does Elicio Therapeutics Inc meet Warren Buffetts criteriaExit Point & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Will Elicio Therapeutics (ELTX) Stock Recover Soon | Price at $10.02, Down 2.65%Community Sell Signals - Cổng thông tin điện tử tỉnh Lào Cai
Aug Technicals: Does Elicio Therapeutics Inc meet Warren Buffetts criteriaQuarterly Market Review & Comprehensive Market Scan Insights - baoquankhu1.vn
Will Elicio Therapeutics (ELTX) Stock Hit Record Highs | Price at $9.90, Down 1.88%High Conviction Picks - Cổng thông tin điện tử tỉnh Lào Cai
ELTX PE Ratio & Valuation, Is ELTX Overvalued - Intellectia AI
JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX) - The Globe and Mail
Discipline and Rules-Based Execution in ELTX Response - Stock Traders Daily
Elicio Therapeutics Inc (9HA.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Fund Flows: Is Elicio Therapeutics Inc a momentum stock2026 Patterns & Reliable Price Action Trade Plans - baoquankhu1.vn
Can Elicio Therapeutics Inc lead its sector in growthMarket Volume Summary & Stock Timing and Entry Methods - baoquankhu1.vn
ELTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Elicio Therapeutics (ELTX) price target increased by 12.90% to 17.85 - MSN
ELTX Stock Quote - richtv.io
Behavioral Patterns of ELTX and Institutional Flows - Stock Traders Daily
Earnings Report: Does Elicio Therapeutics Inc offer margin of safetyQuarterly Risk Review & Weekly High Return Forecasts - baoquankhu1.vn
If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan
How do insiders feel about Elicio Therapeutics IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Macro: How do insiders feel about Elicio Therapeutics IncWeekly Trend Recap & Daily Profit Focused Screening - baoquankhu1.vn
Surprises Report: What are the future prospects of Elicio Therapeutics Inc2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Elicio Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 9HA | US28657F1030 - marketscreener.com
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know - Yahoo Finance
Valuation Update: Can Elicio Therapeutics Inc benefit from deglobalization2026 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Launches New $100 Million ATM Program - The Globe and Mail
Elicio Therapeutics Reports Inducement Grants - Elicio Therapeutics
Biotech new hire lands 1,600 stock options at Elicio Therapeutics - Stock Titan
Elicio Therapeutics, Inc. Enters At Market Issuance Sales Agreement for Up to $400 Million with Nasdaq Listing - Minichart
Rodman & Renshaw initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
[EFFECT] Elicio Therapeutics, Inc. SEC Filing - Stock Titan
Elicio Therapeutics launches new $100 million at-the-market stock offering - Investing.com India
Elicio Therapeutics Launches $100M At-The-Mar... - Benzinga
Elicio Therapeutics Launches $100 Million ATM Program With B. Riley, JonesTrading and Ladenburg - TradingView
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):